Introduction:
Naobios SAS and Sumagen Co. Ltd have partnered to develop an HIV vaccine. Naobios will provide bioprocess development and GMP production of clinical batches of Sumagen’s virus-based HIV vaccine candidate. The vaccine candidate is based on a new highly attenuated rVSV viral vector platform technology. The partnership aims to confirm the safety and efficacy of the vaccine candidate in a Phase I clinical trial and prepare it for Phase II clinical trials.
- Naobios will provide bioprocess development and GMP production of clinical batches of Sumagen’s virus-based HIV vaccine candidate.
- The vaccine candidate is based on a new highly attenuated rVSV viral vector platform technology.
- The partnership aims to confirm the safety and efficacy of the vaccine candidate in a Phase I clinical trial.
- Naobios will also perform further process development to prepare the HIV-1 vaccine for Phase II clinical trials.
- The partnership aims to develop a vaccine for HIV, which has been a challenging task due to the large number of genetically variable forms of the virus.
Conclusion:
Naobios and Sumagen have partnered to develop an HIV vaccine using a novel viral vector technology. The partnership aims to confirm the safety and efficacy of the vaccine candidate in clinical trials and further develop the vaccine for future phases. This partnership is a significant step towards developing an effective HIV vaccine, which has been a long-standing challenge in medical research.
